Trillium Therapeutics Inc (TRIL)

[Whalatane]

TRIL in Bloomberg this am

For Trillium investors that have stuck with its revival led by chief executive Jan Skvarka, the payout has been massive. The stock has surged 4,550% since Skvarka joined the company last September and is the top stock by a mile on Canada’s S&P/TSX Composite Index this year -- skyrocketing past tech behemoth Shopify Inc. and a bevy of gold miners by more than tenfold.

The next catalyst for the Cambridge, Massachusetts-based biotech firm will be updated results from a pair of cancer drugs at the American Society of Hematology meeting next month. Promising data have been the key driver of the stock’s surge and fresh results could spark a move higher, according to analysts.

Kiwi